Physician profile
Daniel Watrous
NPI 1841246568
$17,166.09
in general payments reported to CMS, 2019-2025
36 companies · $4,274 in 2025
The $4,274 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,496 · 2020: $270 · 2021: $1,227 · 2022: $2,259 · 2023: $2,668 · 2024: $2,971 · 2025: $4,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,086 · Consulting Fee: $1,800 · Education: $28.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,085.82 |
| Consulting Fee | $1,800.00 |
| Education | $28.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,525.20 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,007.95 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,905.01 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Glaxosmithkline, LLC. | $899.40 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $883.84 | 2019-2025 | |
| Ucb, INC. | $728.21 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $540.17 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $439.71 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $348.64 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.02 | 2023-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $335.24 | 2023-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $293.28 | 2022-2025 | Lupkynis |
| Celgene Corporation | $244.72 | 2019 | |
| Pfizer INC. | $219.43 | 2021-2025 | |
| Genentech USA, INC. | $217.54 | 2019-2025 | Actemra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205.12 | 2022-2025 | Taltz |
| Genzyme Corporation | $140.60 | 2019-2024 | |
| Organon LLC | $120.57 | 2023-2025 | Renflexis, Hadlima |
| Janssen Scientific Affairs, LLC | $118.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $96.45 | 2023-2024 | Strensiq |
| Medtronic Vascular, INC. | $78.77 | 2019 | |
| Mallinckrodt Hospital Products INC. | $75.46 | 2021-2025 | Acthar |
| Kiniksa Pharmaceuticals, Ltd. | $62.65 | 2021-2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $52.40 | 2023 | Idacio |
| Radius Health, INC. | $42.90 | 2024-2025 | |
| Medexus Pharma, INC. | $35.34 | 2019 | |
| Sandoz INC. | $29.20 | 2025 | Jubbonti |
| Octapharma USA, INC. | $27.90 | 2024 | Octagam Immune Globulin (Human) |
| Celltrion USA INC. | $23.07 | 2023 | Yuflyma |
| Incyte Corporation | $22.68 | 2025 | Opzelura |
| Kyowa Kirin, INC. | $20.71 | 2025 | |
| Almatica Pharma LLC | $19.98 | 2025 | Teriparatide |
| Ipsen Biopharmaceuticals, INC | $18.12 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.35 | 2024 | |
| Alvogen INC | $15.70 | 2025 | Teriparatide |
| Sanofi-Aventis U.S. LLC | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Watrous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.